Angiogenesis and vascular endothelial growth factors in intraocular tumors.

Abstract

The role of angiogenesis in tumors appears obvious: without vessels, tumors cannot grow. However, the long-held belief that all human solid tumors are angiogenesis-dependent has been challenged by the universally disappointing results of anti-angiogenesis therapy in cancer. This may be explained by the fact that cooption of preexisting vasculature as a primary or secondary mechanism of tumor vascularization is more important than previously thought. Nevertheless, anti-angiogenesis therapy may play an important (adjuvant) role in the prevention of metastases of intraocular tumors (uveal melanoma and retinoblastoma). Antivascular endothelial growth factor therapy already plays an important role in the management of irradiation complications in tumor eyes.

• Authors: Guy S Missotten, Reinier O Schlingemann, Martine J Jager
• Journal: Developments in ophthalmology (Dev Ophthalmol) Vol. 46 Pg. 123-132 ( 2010) ISSN: 1662-2790 [Electronic] Switzerland
• PMID: 20703038 (Publication Type: Journal Article)
• Copyright: Copyright 2010 S. Karger AG, Basel.

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Glucocorticoids
• Vascular Endothelial Growth Factor A
• Triamcinolone
• Bevacizumab
• Ranibizumab

Topics

• Angiogenesis Inhibitors (administration & dosage)
• Animals
• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Chronic Disease
• Eye Neoplasms (complications, metabolism, radiotherapy, secondary)
• Glaucoma, Neovascular (drug therapy, etiology)
• Glucocorticoids (administration & dosage)
• Humans
• Inflammation (complications)
• Injections, Intraocular
• Neovascularization, Pathologic (etiology)
• Radiation Injuries (complications)
• Ranibizumab
• Retinal Diseases (drug therapy, etiology, metabolism)
• Triamcinolone (administration & dosage)
• Vascular Endothelial Growth Factor A (administration & dosage, metabolism)